Source comparison
Peak GH Output vs Sustained Elevation
Hexarelin's acute GH release reaches 40–60 ng/mL within 20–30 minutes post-injection in human trials. A level comparable to pharmacological GHRH (growth hormone-releasing hormone) administration. That magnitude matters in research contexts where the goal is to
This comparison does not assign a generated winner or score.
- Hexarelin's acute GH release reaches 40–60 ng/mL within 20–30 minutes post-injection in human trials. A level comparable to pharmacological GHRH (growth hormone-releasing hormone) administration. That magnitude matters in research contexts where the goal is to study acute GH effects on lipolysis, glucose metabolism, or anabolic signalling cascades that respond to peak hormone concentration rather than AUC (area under the curve).
- MK-677 produces a blunted peak. Typically 10–20 ng/mL. But maintains elevated GH throughout the 24-hour dosing window. The total daily GH secretion (measured as AUC) ends up higher with MK-677 despite the lower peak because the hormone never returns to baseline between pulses. This creates a fundamentally different physiological environment: Hexarelin mimics a supraphysiological GH injection, while MK-677 extends the natural pulsatile rhythm without eliminating it.
- Research from the University of Virginia published in JCEM demonstrated that six months of daily MK-677 increased mean 24-hour GH concentration by 89% and IGF-1 by 79% in healthy older adults. Outcomes that would require twice-daily Hexarelin dosing in the first two weeks, then progressively more frequent dosing as tolerance built. The clinical implication: if your research question involves chronic GH elevation. Body composition changes, bone density modulation, sleep architecture. MK-677's durability outweighs Hexarelin's higher peak.